<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Watanabe Y</submitter><funding>MEXT | Japan Society for the Promotion of Science</funding><funding>MEXT | Japan Society for the Promotion of Science (JSPS)</funding><funding>Japan Agency for Medical Research and Development</funding><funding>Japan Agency for Medical Research and Development (AMED)</funding><pagination>e2322363121</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11046696</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>121(17)</volume><pubmed_abstract>Anti-microbial resistance (AMR) is one of the greatest threats to global health. The continual battle between the emergence of AMR and the development of drugs will be extremely difficult to stop as long as traditional anti-biotic approaches are taken. In order to overcome this impasse, we here focused on the type III secretion system (T3SS), which is highly conserved in many Gram-negative pathogenic bacteria. The T3SS is known to be indispensable in establishing disease processes but not essential for pathogen survival. Therefore, T3SS inhibitors may be innovative anti-infective agents that could dramatically reduce the evolutionary selective pressure on strains resistant to treatment. Based on this concept, we previously identified a polyketide natural product, aurodox (AD), as a specifi</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>PurA is the main target of aurodox, a type III secretion system inhibitor.</pubmed_title><pmcid>PMC11046696</pmcid><funding_grant_id>JP15K08001</funding_grant_id><funding_grant_id>JP21am0101096</funding_grant_id><funding_grant_id>JP23K06531</funding_grant_id><funding_grant_id>JP22ama121035</funding_grant_id><funding_grant_id>JP22gm1610003</funding_grant_id><pubmed_authors>Honsho M</pubmed_authors><pubmed_authors>Suzuki T</pubmed_authors><pubmed_authors>Watanabe Y</pubmed_authors><pubmed_authors>Kanoh N</pubmed_authors><pubmed_authors>Haneda T</pubmed_authors><pubmed_authors>Honma S</pubmed_authors><pubmed_authors>Kuwae A</pubmed_authors><pubmed_authors>Abe A</pubmed_authors><pubmed_authors>Iwatsuki M</pubmed_authors><pubmed_authors>Omura S</pubmed_authors><pubmed_authors>Kimishima A</pubmed_authors><pubmed_authors>Suga T</pubmed_authors><pubmed_authors>Iwabuchi Y</pubmed_authors><pubmed_authors>Asami Y</pubmed_authors><pubmed_authors>Matsui H</pubmed_authors><pubmed_authors>Hanaki H</pubmed_authors></additional><is_claimable>false</is_claimable><name>PurA is the main target of aurodox, a type III secretion system inhibitor.</name><description>Anti-microbial resistance (AMR) is one of the greatest threats to global health. The continual battle between the emergence of AMR and the development of drugs will be extremely difficult to stop as long as traditional anti-biotic approaches are taken. In order to overcome this impasse, we here focused on the type III secretion system (T3SS), which is highly conserved in many Gram-negative pathogenic bacteria. The T3SS is known to be indispensable in establishing disease processes but not essential for pathogen survival. Therefore, T3SS inhibitors may be innovative anti-infective agents that could dramatically reduce the evolutionary selective pressure on strains resistant to treatment. Based on this concept, we previously identified a polyketide natural product, aurodox (AD), as a specifi</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2025-04-04T08:17:01.486Z</modification><creation>2025-04-04T08:17:01.486Z</creation></dates><accession>S-EPMC11046696</accession><cross_references><pubmed>38640341</pubmed><doi>10.1073/pnas.2322363121</doi></cross_references></HashMap>